Limitations of the Laboratory Monitoring of Heparin Therapy

Mike Greaves

doi:10.1055/s-0037-1612960

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(01): 163-164
DOI: 10.1055/s-0037-1612960

Scientific and Standardization Committee Communications

Schattauer GmbH

Limitations of the Laboratory Monitoring of Heparin Therapy

Scientific and Standardization Committee Communications: On behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis

Authors

Mike Greaves

Abstract

Full Text

References

References
1 Hoppensteadt DA, Jeske W, Fareed J, Bermes EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coag Fibrinolysis 1995; S57-S64.
2 Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin. Ann Intern Med 1993; 119: 104-9.
3 D’Angelo A, Seveso MP, D’Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on APTT-implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297-306.
4 Contant G, Gouault-Heilmann M, Martinoli J. Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thrombosis Research 1983; 31: 365-74.
5 Ray MJ. An artefact related to the sample volume to the blood collection vial size which affects the APTTs of specimens taken to monitor heparin therapy. Thromb Haemost 1991; 66: 387-8.
6 Van den Besselaar AMHP, Meevwisse-Braun J, Jansen-Gruter R, Bertina RM. Monitoring heparin therapy by the APTT – the effect of pre-analytical conditions. Thromb Haemost 1987; 57: 226-31.
7 Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparin. Arch Intern Med 1995; 155: 601-7.
8 Hemker HC, Béguin S. The activity of heparin in the presence and absence of calcium ions; why the anti-Xa activity of LMW heparins is about two times overestimated. Thromb Haemost 1993; 70: 717-8.
9 Peyrou V, Béguin S, Boneu B, Hemker HC. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma – the need for using absolute anti-factor Xa and antithrombin activities. Thromb Haemost 1997; 77: 312-6.
10 Eriksson BI, Soderberg K, Widlund W, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular weight heparins and unfractionated heparin in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
11 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998; 82: 3L-10L.
12 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain prothrombin activation velocity in whole plasma independent of thrombin decay process. Thromb Haemost 1986; 56: 9-17.
13 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
14 Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989a 61: 397-401.
15 Béguin S, Mardiguian J, Lindhout T, Hemker H. The mode of action of low molecular weight heparin preparation (PK1069) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989b 61: 30-4.
16 Béguin S, Wielders S, Lormeau JC, Hemker HC. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41.
17 Béguin S, Hemker HC. Mode of action of enoxaparin in plasma. Acta Chir Scand Suppl 1990; 556: 51-6.
18 Kitchen S, Lampietro R, Woolley AM, Preston FE. Anti-Xa monitoring during treatment of LMWH or danaparoid: Inter-assay variability. Thromb Haemost 1999; 82: 1289-93.
19 Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight or unfractionated heparin. Clin Lab Haematol 1999; 21: 55-60.
20 Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993; 23: 89-98.
21 Alhenc-Gélas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JM. Adjusted versus fixed doses of low molecular weight heparin Fragmin in the treatment of deep venous thrombosis. Thromb Haemost 1994; 71: 698-702.
22 Niewenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.
23 Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker HC, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyperand hypocoagulability. Thromb Haemost 1997; 77: 629-36.